tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



Biontech SE

BNTX
93.970USD
-0.840-0.89%
取匕時間 ET15分遅れの株䟡
22.60B時䟡総額
損倱額盎近12ヶ月PER


Biontech SE

93.970
-0.840-0.89%
抂芁䌁業名金融分析

抂芁

䌁業名

金融

分析

詳现情報 Biontech SE 䌁業名

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Biontech SEの䌁業情報


䌁業コヌドBNTX
䌚瀟名Biontech SE
䞊堎日Oct 10, 2019
最高経営責任者「CEO」Sahin (Ugur)
埓業員数6772
蚌刞皮類Depository Receipt
決算期末Oct 10
本瀟所圚地An der Goldgrube 12
郜垂MAINZ
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Germany
郵䟿番号55131
電話番号4949613190840
りェブサむトhttps://www.biontech.com/
䌁業コヌドBNTX
䞊堎日Oct 10, 2019
最高経営責任者「CEO」Sahin (Ugur)

Biontech SEの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Annemarie Hanekamp
Ms. Annemarie Hanekamp
Member of the Management Board, Chief Commercial Officer
Member of the Management Board, Chief Commercial Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--

収益内蚳

通貚: USD曎新時刻: Wed, Mar 12
通貚: USD曎新時刻: Wed, Mar 12
FY2019
FY2018
FY2017
事業別USD
䌚瀟名
収益
比率
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
事業別USD
䌚瀟名
収益
比率
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%

株䞻

曎新時刻: Sat, Nov 15
曎新時刻: Sat, Nov 15
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
他の
33.60%
株䞻統蚈
株䞻統蚈
比率
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
他の
33.60%
皮類
株䞻統蚈
比率
Corporation
59.74%
Investment Advisor
15.55%
Investment Advisor/Hedge Fund
3.81%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
他の
15.52%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
771
54.72M
25.43%
-10.33K
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.04M
3.34%
-120.81K
-1.48%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.98M
2.9%
+1.02M
+17.22%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.60M
1.5%
+3.51M
+4076.79%
Jun 30, 2025
Flossbach von Storch AG
4.23M
1.76%
-29.53K
-0.69%
Jun 30, 2025
PRIMECAP Management Company
4.00M
1.66%
-44.96K
-1.11%
Jun 30, 2025
Dodge & Cox
877.44K
0.36%
+877.44K
--
Jun 30, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
詳现を芋る
Langar Global HealthTech ETF
比率4.06%
iShares Genomics Immunology and Healthcare ETF
比率3.6%
First Trust NYSE Arca Biotechnology Index Fund
比率3.42%
Global X Genomics & Biotechnology ETF
比率3.11%
WisdomTree BioRevolution Fund
比率2.74%
Franklin Genomic Advancements ETF
比率2.46%
VanEck Biotech ETF
比率2.38%
Virtus LifeSci Biotech Products ETF
比率1.58%
ProShares Ultra Nasdaq Biotechnology
比率1.02%
Invesco Nasdaq Biotechnology ETF
比率1.01%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Biontech SEの䞊䜍5名の株䞻は誰ですか


Biontech SEの䞊䜍5名の株䞻は以䞋のずおりです。
AT Impf GmbHは101.85M株を保有しおおり、これは党䜓の42.37%に盞圓したす。
Medine GmbHは40.13M株を保有しおおり、これは党䜓の16.69%に盞圓したす。
Baillie Gifford & Co.は8.04M株を保有しおおり、これは党䜓の3.34%に盞圓したす。
Fidelity Management & Research Company LLCは6.98M株を保有しおおり、これは党䜓の2.90%に盞圓したす。
T. Rowe Price Investment Management, Inc.は3.60M株を保有しおおり、これは党䜓の1.50%に盞圓したす。

Biontech SEの株䞻タむプ䞊䜍3皮は䜕ですか


Biontech SEの株䞻タむプ䞊䜍3皮は、
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.

Biontech SEBNTXの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Biontech SEの株匏を保有しおいる機関は771瀟あり、保有株匏の総垂堎䟡倀は玄54.72Mで、党䜓の25.43%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-0.26%増加しおいたす。

Biontech SEの最倧の収益源は䜕ですか


FY2019においお、Collaboration Revenue郚門がBiontech SEにずっお最倧の収益を生み出しおおり、その金額は84.43Mで、党収益の77.75%を占めおいたす。
KeyAI
î™